Evotec (ETR:EVT) has been given a €17.00 ($20.24) price target by research analysts at Deutsche Bank in a research report issued to clients and investors on Tuesday. The brokerage currently has a “buy” rating on the stock. Deutsche Bank’s price objective suggests a potential upside of 46.61% from the company’s previous close.
A number of other analysts also recently commented on EVT. Berenberg Bank set a €16.00 ($19.05) price objective on shares of Evotec and gave the stock a “neutral” rating in a report on Thursday, August 17th. Oddo Securities set a €14.00 ($16.67) price objective on shares of Evotec and gave the stock a “neutral” rating in a report on Friday, August 11th. Finally, Oddo Bhf set a €20.00 ($23.81) price objective on shares of Evotec and gave the stock a “buy” rating in a report on Wednesday, November 29th.
Shares of Evotec (ETR:EVT) opened at €11.60 ($13.80) on Tuesday. Evotec has a 1-year low of €5.93 ($7.06) and a 1-year high of €22.50 ($26.79).
Evotec Company Profile
Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services.
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.